The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2022
Filed:
Jun. 29, 2018
Applicant:
Beijing Tide Pharmaceutical Co., Ltd., Beijing, CN;
Inventors:
Yanping Zhao, Beijing, CN;
Hongjun Wang, Beijing, CN;
Gong Li, Beijing, CN;
Yuanyuan Jiang, Beijing, CN;
Xiang Li, Beijing, CN;
Bin Liu, Beijing, CN;
Weiting Zhong, Beijing, CN;
Kai Liu, Beijing, CN;
Fajie Li, Beijing, CN;
Liying Zhou, Beijing, CN;
Yanan Liu, Beijing, CN;
Assignee:
BEIJING TIDE PHARMACEUTICAL CO., LTD., Beijing, CN;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07D 471/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 471/10 (2006.01); C07D 519/00 (2006.01); C07D 491/048 (2006.01); C07D 513/04 (2006.01); C07D 417/14 (2006.01); C07D 453/02 (2006.01); C07F 9/6558 (2006.01); A61P 37/00 (2006.01); A61K 31/416 (2006.01); A61K 31/506 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
C07D 403/14 (2013.01); A61K 31/416 (2013.01); A61K 31/506 (2013.01); A61P 29/00 (2018.01); A61P 37/00 (2018.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 453/02 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01); C07F 9/65583 (2013.01);
Abstract
The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).